These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18400837)

  • 1. Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis--data from the RAPIT study.
    de Jong Z; Munneke M; Vilim V; Zwinderman AH; Kroon HM; Ronday HK; Lems WF; Dijkmans BA; Breedveld FC; Vliet Vlieland TP; Hazes JM; Degroot J
    Rheumatology (Oxford); 2008 Jun; 47(6):868-71. PubMed ID: 18400837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis].
    Marti C; Neidhart M; Gerber T; Hauser N; Michel BA; Häuselmann HJ
    Z Rheumatol; 1999 Apr; 58(2):79-87. PubMed ID: 10408068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis.
    Andersson ML; Svensson B; Petersson IF; Hafström I; Albertsson K; Forslind K; Heinegård D; Saxne T
    BMC Musculoskelet Disord; 2013 Aug; 14():229. PubMed ID: 23915292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study.
    Roux-Lombard P; Eberhardt K; Saxne T; Dayer JM; Wollheim FA
    Rheumatology (Oxford); 2001 May; 40(5):544-51. PubMed ID: 11371663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic laboratory markers of joint damage in rheumatoid arthritis.
    Lindqvist E; Eberhardt K; Bendtzen K; Heinegård D; Saxne T
    Ann Rheum Dis; 2005 Feb; 64(2):196-201. PubMed ID: 15458956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis.
    Wisłowska M; Jabłońska B
    Clin Rheumatol; 2005 Jun; 24(3):278-84. PubMed ID: 15940561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term high intensity exercise and damage of small joints in rheumatoid arthritis.
    de Jong Z; Munneke M; Zwinderman AH; Kroon HM; Ronday KH; Lems WF; Dijkmans BA; Breedveld FC; Vliet Vlieland TP; Hazes JM; Huizinga TW
    Ann Rheum Dis; 2004 Nov; 63(11):1399-405. PubMed ID: 15479889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis.
    Skoumal M; Kolarz G; Klingler A
    Scand J Rheumatol; 2003; 32(3):156-61. PubMed ID: 12892252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.
    Young-Min S; Cawston T; Marshall N; Coady D; Christgau S; Saxne T; Robins S; Griffiths I
    Arthritis Rheum; 2007 Oct; 56(10):3236-47. PubMed ID: 17907159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cartilage Oligomeric Matrix Protein (COMP) in systemic sclerosis (SSc): role in disease severity and subclinical rheumatoid arthritis overlap.
    Gheita TA; Hussein H
    Joint Bone Spine; 2012 Jan; 79(1):51-6. PubMed ID: 21497537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis.
    Morozzi G; Fabbroni M; Bellisai F; Cucini S; Simpatico A; Galeazzi M
    Clin Rheumatol; 2007 Aug; 26(8):1335-8. PubMed ID: 17285224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression.
    Syversen SW; Goll GL; van der Heijde D; Landewé R; Gaarder PI; Odegård S; Haavardsholm EA; Kvien TK
    J Rheumatol; 2009 Feb; 36(2):266-72. PubMed ID: 19132792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis.
    Andersson ML; Thorstensson CA; Roos EM; Petersson IF; Heinegård D; Saxne T
    BMC Musculoskelet Disord; 2006 Dec; 7():98. PubMed ID: 17156423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet.
    Fex E; Eberhardt K; Saxne T
    Br J Rheumatol; 1997 Nov; 36(11):1161-5. PubMed ID: 9402859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project.
    Clark AG; Jordan JM; Vilim V; Renner JB; Dragomir AD; Luta G; Kraus VB
    Arthritis Rheum; 1999 Nov; 42(11):2356-64. PubMed ID: 10555031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cartilage oligomeric matrix protein (COMP) in knee osteoarthritis: a novel diagnostic and prognostic biomarker.
    Verma P; Dalal K
    J Orthop Res; 2013 Jul; 31(7):999-1006. PubMed ID: 23423905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a high-intensity weight-bearing exercise program on radiologic damage progression of the large joints in subgroups of patients with rheumatoid arthritis.
    Munneke M; de Jong Z; Zwinderman AH; Ronday HK; van Schaardenburg D; Dijkmans BA; Kroon HM; Vliet Vlieland TP; Hazes JM
    Arthritis Rheum; 2005 Jun; 53(3):410-7. PubMed ID: 15934121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy.
    Niki Y; Takeuchi T; Nakayama M; Nagasawa H; Kurasawa T; Yamada H; Toyama Y; Miyamoto T
    PLoS One; 2012; 7(5):e37447. PubMed ID: 22629396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis.
    Kullich WC; Mur E; Aglas F; Niksic F; Czerwenka C
    Clin Exp Rheumatol; 2006; 24(2):155-60. PubMed ID: 16762150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment.
    Skoumal M; Haberhauer G; Feyertag J; Kittl EM; Bauer K; Dunky A
    Rheumatol Int; 2006 Sep; 26(11):1001-4. PubMed ID: 16485108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.